Deep Track Capital LP Acquires 5,265,000 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Deep Track Capital LP boosted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 42.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,791,486 shares of the biopharmaceutical company's stock after buying an additional 5,265,000 shares during the period. Dynavax Technologies makes up about 8.5% of Deep Track Capital LP's investment portfolio, making the stock its largest position. Deep Track Capital LP owned about 13.53% of Dynavax Technologies worth $227,197,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of DVAX. Barclays PLC raised its position in shares of Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after buying an additional 175,118 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Dynavax Technologies in the 3rd quarter valued at approximately $89,000. Franklin Resources Inc. raised its holdings in Dynavax Technologies by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company's stock valued at $862,000 after acquiring an additional 4,459 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after acquiring an additional 1,457 shares during the period. Finally, Nordea Investment Management AB grew its holdings in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock worth $10,034,000 after purchasing an additional 232,690 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on DVAX shares. StockNews.com lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday. HC Wainwright restated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th.

Dynavax Technologies Price Performance

Shares of DVAX stock opened at $10.93 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The stock's fifty day simple moving average is $12.49 and its 200 day simple moving average is $12.59. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of 60.74 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.